Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease?-Reference-Cited by-同舟云学术

Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease?

Published:2010-08-11 Issue:9 Volume:19 Page:1039-1048
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Irwin Nigel¹,Gault Victor¹,Flatt Peter R²

Affiliation:

1. SAAD Centre for Diabetes and Pharmacy, School of Biomedical Sciences, University of Ulster, Cromore Road, Coleraine, Co. Londonderry, BT52 1SA, Northern Ireland, UK ; ;

2. SAAD Centre for Diabetes and Pharmacy, School of Biomedical Sciences, University of Ulster, Cromore Road, Coleraine, Co. Londonderry, BT52 1SA, Northern Ireland, UK

Publisher

Informa Healthcare

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1517/13543784.2010.513381

Reference78 articles.

1. Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP)

2. Gastric Inhibitory Polypeptide: Its Physiologic Release and Insulinotropic Action in the Dog

3. Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes

4. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results

5. Preparation of highly active enterogastrone

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes?;Journal of Endocrinology;2024-06-11

2. RYGB surgery has modest effects on intestinal morphology and gut hormone populations in the bypassed biliopancreatic limb but causes reciprocal changes in GLP-2 and PYY in the alimentary limb;PLOS ONE;2023-05-25

3. GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy;Expert Opinion on Pharmacotherapy;2023-03-24

4. Role of a Dual Glucose-Dependent Insulinotropic Peptide (GIP)/Glucagon-like Peptide-1 Receptor Agonist (Twincretin) in Glycemic Control: From Pathophysiology to Treatment;Life;2021-12-25

5. Pharmacology of Gut Hormone Mimetics for Obesity and Diabetes;Reference Module in Biomedical Sciences;2021